OAM
CTMX icon

Oxford Asset Management’s CytomX Therapeutics CTMX Stock Holding History

Oxford Asset Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-212,183
Closed -$1.76M – 472
2019
Q4 		$1.76M Buy
212,183
+133,900
+171% +$903K 0.05% 498
2019
Q3 		$578K Buy
+78,283
New +$772K 0.01% 1205
2018
Q3 		– Sell
-80,339
Closed -$1.84M – 1720
2018
Q2 		$1.84M Buy
80,339
+3,041
+4% +$77.7K 0.04% 713
2018
Q1 		$2.2M Sell
77,298
-98,435
-56% -$2.81M 0.05% 522
2017
Q4 		$3.88M Buy
175,733
+9,654
+6% +$200K 0.08% 296
2017
Q3 		$3M Buy
166,079
+134,484
+426% +$2.1M 0.06% 408
2017
Q2 		$490K Sell
31,595
-70
-0.2% -$1.05K 0.01% 1127
2017
Q1 		$547K Buy
31,665
+6,995
+28% +$92.1K 0.01% 1026
2016
Q4 		$271K Buy
+24,670
New +$299K 0.01% 665

Other funds holding CTMX

Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Oxford Asset Management's CTMX Position: Q1 2020 in Review

Oxford Asset Management sold out of CytomX Therapeutics (CTMX) in Q1 2020, closing a stake of 212,183 shares — an estimated $1.76M sold.

Oxford Asset Management first reported a position in CTMX in Q4 2016 and held it in 9 quarters. The position peaked at $3.88M in Q4 2017. 117 funds tracked by Wall St. Rank hold CTMX as of Q1 2020.

  • Oxford Asset Management reported no remaining CytomX Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Oxford Asset Management sold 212,183 CytomX Therapeutics shares in Q1 2020, an estimated $1.76M.
  • Oxford Asset Management first reported a position in CytomX Therapeutics in Q4 2016 and held it in 9 quarters.
  • Oxford Asset Management's CytomX Therapeutics position peaked at $3.88M in Q4 2017.
  • 117 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.